medigraphic.com
ISSN 1029-3035 (Electronic)

2011, Number 1

<< Back Next >>

Mediciego 2011; 17 (1)

Evaluation of a renal cell carcinoma operative patient since three years with chronic kidney disease diagnosis

Romero SO, Inda MAJ, Pasalodos DN, de la Paz GCJ, Suárez ALT, Fernández EMM

Language: Spanish
References: 23
Page:
PDF size: 65.97 Kb.


ABSTRACT

The presence of renal cell carcinoma during the evolution of an autosomal dominant polycystic kidney disease is very rare and little reported in international literature. Clinical manifestations of renal cell carcinoma are often late, so that approximately one-third of patients have metastatic disease at the time of diagnosis. It is reported a case of polycystic renal disease associated with renal cell carcinoma operated three years ago with conservative clinical treatment, besides he had been diagnosticated with an advanced chronic kidney disease who had mantained an stable evolution.


REFERENCES

  1. Davis F, Coles GA, Harper PS. Polycystic kidney disease reevaluated. A population based study. Q J Med 1991; 79:477.

  2. Michalsky JM. Kidney, renal pelvis, and ureter. En: Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich RK, editores. Principles and practice of radiation oncology. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1649-63.

  3. Keith DS, Torres UE, King BF. Renal cell carcinoma in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994; 4(9):661-9.

  4. De Riese W, Goldenberg K, Allhoff E, Stief C, Schlick R, Liedke S, et al. Metastatic renal cell carcinoma (RCC): spontaneous regression, long-term survival and late recurrence. Int Urol Nephrol. 1991; 23(1):13-25.

  5. Torra R, Viribay M, Tellería D. Seven novel mutations of the PKD-2 genes in families with autosomal dominant polycystic kidney disease. Kidney Int. 1999; 56:28-30.

  6. Daoust MC, Reynolds DM, Bichet DG, Somlo S. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease. Genomic. 1995; 25:733-5.

  7. López Beltrán A, Scarpelli M, Montironi R. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006; 49: 798-805.

  8. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World Health Organization classification of tumours. Pathology and genetics of tumors of the urinary system and male genital organs. Lyon: IARC Press; 2004.

  9. Rodríguez JI, Soria P, Sola A, López M, Bustos M, Rodríguez A, et al. Regresión espontánea tras nefrectomía de carcinoma renal metastásico. Oncología (Barcelona). 2006; 29(6):23-32.

  10. Young RC. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions? N Engl J Med. 1998; 338(18):1305-6.

  11. Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, editors. Kidney Cancer - v. 2. [Internet]. Philadelphia: NCCN Clinical Practice Guidelines in Oncology; 2005. [citado 12 Oct 2010]. Disponible en http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf

  12. Michael A, Pandha HS. Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncol.2003; 4(4):215-23.

  13. Ganvoort RT, van der Heij B, Stegeman CA. Trends in the incidence of treated end-stage renal failure in the Netherlands: hope for the future? Kidney Int. 2004; (Suppl): 57-510.

  14. Uhlig K, Macleod A, Craid J. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 70: 2058-2065.

  15. El Nahas ME. The global challenge of chronic kidney disease (Nephrology Forum). Kidney Int. 2005; 68: 2918-2929.

  16. Hallan SI, Coresh J, Astor BC. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006; 17: 2275-2285.

  17. Go AS, Chertow GM, Fan D. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-1305.

  18. Weiner DE, Tabatabai S, Tighiouart H. Cardiovascular outcomes and all-cause mortality: exploring the intereaction between CDK and cardiovascular disease. Am J Kidney Dis. 2006; 48: 392-401.

  19. Mann JFE, Gerstein HC, Pogue J. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Inter Med. 2006; 134: 629-636.

  20. Yuyun MF, Adler Al, Warenham NJ. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events? Curr Opin Nephrol Hypertens. 2006; 14: 271-276.

  21. Courser WG. Un llamado a la acción en el Día Mundial del Riñón. Kidney Int. 2007; 3:156-157.

  22. Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, et al. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes prediálisis (Revisión Cochrane traducida). [citado 29 Oct 2010]. En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com.

  23. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006: 47(5 Suppl 3):S11-S145.




2020     |     www.medigraphic.com